

# Supplemental Information

**Table S1.** Birth incidence of different genotypes.


Genotype	<i>Rheb1</i> <sup>F/F</sup> ; $\alpha$ MHC-Cre	<i>Rheb1</i> <sup>F/+</sup> ; $\alpha$ MHC-Cre	<i>Rheb1</i> <sup>F/F</sup>	<i>Rheb1</i> <sup>F/+</sup>
Real value	70 (23.3%)	65 (21.7%)	144 (48%)	156 (52%)
Estimated value	75 (25%)	75 (25%)	150 (50%)	150 (50%)

**Table S2.** Time course of echocardiography at post-natal day 7, 10, and 12.


Parameter	7		10		12	
	CTL (n = 8)	cKO (n = 8)	CTL (n = 8)	cKO (n = 8)	CTL (n = 5)	cKO (n = 5)
IVS;d (mm)	0.33 ± 0.05	0.35 ± 0.06	0.35 ± 0.05	0.31 ± 0.05	0.43 ± 0.03 ***	0.34 ± 0.02 *
IVS;s (mm)	0.47 ± 0.09	0.49 ± 0.13	0.53 ± 0.09	0.43 ± 0.09	0.60 ± 0.07 ‡	0.43 ± 0.07 *
LVID;d (mm)	1.70 ± 0.23	1.94 ± 0.14	2.09 ± 0.19 ‡	2.46 ± 0.43 ***	2.07 ± 0.22 ‡	2.68 ± 0.39 **-***
LVID;s (mm)	0.88 ± 0.32	1.06 ± 0.16	1.05 ± 0.24	1.65 ± 0.58 **,††	1.14 ± 0.19	2.00 ± 0.51 **-†††
LVPW;d (mm)	0.54 ± 0.09	0.49 ± 0.09	0.58 ± 0.09	0.53 ± 0.20	0.59 ± 0.10	0.45 ± 0.11
LVPW;s (mm)	0.82 ± 0.14	0.78 ± 0.16	1.01 ± 0.24	0.74 ± 0.28	0.91 ± 0.19	0.65 ± 0.17
LV Vol; d	8.62 ± 2.92	11.97 ± 2.20	14.37 ± 3.23	22.36 ± 10.49 *††	14.40 ± 3.73	27.15 ± 9.75 **,†††
LV Vol; s	1.82 ± 1.34	2.53 ± 0.94	2.59 ± 1.63	9.52 ± 8.20 *††	3.14 ± 1.33	14.02 ± 8.92 **-†††
%EF	81.39 ± 11.95	78.393 ± 8.59	82.41 ± 8.73	63.06 ± 18.68 **,†	78.72 ± 5.46	52.03 ± 14.64 **,†††
%FS	50.00 ± 14.11	45.38 ± 8.35	49.97 ± 9.37	34.28 ± 13.14 *	45.32 ± 5.31	25.99 ± 8.85 *††
LV Mass	12.81 ± 3.66	16.09 ± 1.88	21.25 ± 6.29 ‡‡	21.79 ± 6.42	22.06 ± 5.30 ‡	23.86 ± 5.78 †
LV Mass Corrected	10.25 ± 2.93	12.87 ± 1.50	17.00 ± 5.03 ‡‡	17.43 ± 5.14	17.65 ± 4.24 ‡‡	20.85 ± 2.80 †

Abbreviation: CTL, Control group (*Rheb1*<sup>F/F</sup>); cKO, cardiac knockout group ( $\alpha$ -MHC-Cre/*Rheb1*<sup>F/F</sup>); IVS;d, intraventricular septal thickness in diastole; IVS;s, intraventricular septal thickness in systole; LVPW;d, LV posterior wall thickness in diastole; LVPW;s, LV posterior wall thickness in systole; LVID;d, LV internal diameter in diastole; LVID;s, LV internal diameter in systole; FS, LV fractional shortening; EF, LV ejection fraction; LV Vol; d, LV volume in diastole; LV Vol; s, LV Volume in systole. \*  $p < 0.05$ , \*\*  $p < 0.01$ , and \*\*\*  $p < 0.001$ , cKO versus CTL. †  $p < 0.05$ , ††  $p < 0.01$ , and †††  $p < 0.001$ , day 10 and 12 versus day 7 respectively in cKO group. ‡  $p < 0.05$ , ‡‡  $p < 0.01$ , and ‡‡‡  $p < 0.001$ , day 10 and 12 versus day 7 respectively in CTL group.


**Figure S1.** Detection of apoptosis. (A) Immunofluorescence. Red indicates cleaved caspase 3; green indicates cTNT; blue indicates DAPI staining of nuclei. Original magnification:  $\times 40$  (Scale bar = 25  $\mu$ m). (B) Quantification of (A) ( $n = 3$ ). Abbreviation: CTL, Control group ( $Rheb1^{F/F}$ ); cKO, cardiac knockout group ( $Rheb1^{F/F}; \alpha MHC-Cre$ ). \*\*  $p < 0.01$ , cKO versus CTL.



**Figure S2.** Detection of autophagy at postnatal day 9 and 12, respectively. (A) Immunofluorescence. Red indicates LC3A/B; green indicates  $\alpha$ -actinin; blue indicates DAPI staining of nuclei. Original magnification:  $\times 40$  (Scale bar = 25  $\mu$ m). (B) Representative Western blots of LC3A/B I and II at postnatal day 9. (C) Quantification of (B) ( $n = 3$ ). (D) Detection of LC3 by qPCR ( $n = 3$ ). (E) Immunofluorescence at day 12. Red indicates LC3A/B; green indicates  $\alpha$ -actinin; blue indicates DAPI staining of nuclei. Original magnification:  $\times 40$  (Scale bar = 10  $\mu$ m). (F) Representative Western blots of LC3A/B I and II at day 12. Abbreviation: CTL, Control group ( $Rheb^{\text{fl/fl}}$ ); cKO, cardiac knockout group ( $Rheb^{\text{fl/fl}}; \alpha\text{MHC-Cre}$ ). \*\*  $p < 0.01$ ; and \*\*\*  $p < 0.001$ , cKO versus CTL.



**Figure S3.** Representative Western blots of ER-stress relative markers at postnatal day 8 and 9 respectively. Abbreviation: ATF4, activated transcription factor 4; PDI, Protein disulfide isomerase; CHOP, C/EBP homologous protein; JNK, c-Jun N-terminal kinase; CTL, Control group (*Rheb1*<sup>F/F</sup>); cKO, cardiac knockout group (*Rheb1*<sup>F/F</sup>;  $\alpha$ MHC-Cre).



© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).